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Abstract
Objective—To use electronic drug monitoring to determine if adherence to HIV antiretroviral 
therapy changes over time, whether changes are linear, and how the declines vary by study.
Design—We conducted a longitudinal study of pooled data from 11 different studies of HIV 
infected adults using antiretroviral therapy. The main outcome was antiretroviral therapy 
adherence (percent of prescribed doses taken) measured by electronic drug monitoring. We 
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modeled and compared changes in adherence over time using repeated measures linear mixed 
effects models and generalized additive mixed models. Indicator variables were used to examine 
the impact of individual studies, and the variation across studies was evaluated using study-
specific parameter estimates calculated by using interaction terms of study and time.
Results—The mean age of the subjects was 41 years, 35% were female, most had high school 
education or less, and 46% were African-American. In generalized additive mixed models, 
adherence declined over time. The generalized additive mixed models further suggested that the 
decline was non-linear, and in both sets of models there was considerable study-to-study 
variability in how adherence changed over time.
Limitations—Findings may not be generalizable to non-US populations or to patients not in 
clinical studies.
Conclusions—Although overall antiretroviral therapy adherence declined with time, not all 
studies showed declines, and a number of patterns of change were seen. Studies that identify 
clinical and organizational factors associated with these different patterns are needed. Models of 
changes in adherence with time should take account of possible non-linear effects.
Keywords
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INTRODUCTION
There is debate about the natural history of adherence to HIV antiretroviral therapy (ART) 
over time. Most studies have shown that ART adherence declines with time,1-9 but some 
suggest that adherence is stable over time,10-12 and still others show improvements over 
time.13-17 There are a number of potential explanations for these discrepant findings, 
including differences in patient populations, country and/or setting, whether study 
populations are ART naïve versus experienced at enrollment, whether the studies were in the 
context of interventions, methods used to assess adherence, and analytic approaches (e.g., 
methods to account for missing data and losses to follow-up).
To better understand the natural history of ART adherence in the United States, we used 
data from the Multisite Adherence Collaboration on HIV study, or MACH14. MACH14 
conducts pooled analyses with individual subject data from 16 studies drawn from 14 
different research groups in 12 states, all of which used electronic data monitoring or EDM. 
Three main study questions were addressed by this research. First, what is the natural history 
of changes in antiretroviral adherence over time? Second, are these changes linear? Third, 
do these changes differ by study?
METHODS
Ethics Statement
MACH 14 is a multisite collaboration. Each of the 16 studies that make up this collaboration 
was approved by that institution's Institutional Review Board.
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Studies and patient selection
MACH 14 included both observational (n=4) and intervention (n=12) studies. The process is 
described in detail elsewhere.18-21 To be included in this analysis, monitoring had to be 
continuous and data on whether patients were ART naïve had to be available. This excluded 
four studies that assessed adherence only in the weeks prior to a study visit and one study 
without ART naïve information, leaving 11 eligible studies. We use the term “study” and 
not “site” to avoid confusion between the sites where the study took place and the sites 
where patients received HIV clinical care, which was not necessarily the same for the 
studies that recruited patients from multiple care sites.
Because we were interested in the natural history of changes in ART adherence over time, 
we only included control patients in adherence intervention trials. Of the 1456 patients in the 
11 eligible studies, 916 were either in observational studies or in control arms of 
intervention studies, and formed the analytic sample. The number of patients, intervention 
status, and length of follow up for each of the 11 included studies are shown in Table 1. 
Patients were followed for up to 12 months.
Variables
We defined the dependent variable as ART adherence. For each patient, the time of 
observation was divided into one month periods. Adherence was operationalized as the 
number of observed openings divided by the number of prescribed doses. Typically one 
antiretroviral was monitored using EDM, but when more than one was monitored, we 
calculated an average from all monitored medications over the month. Adherence was 
summarized by month across the whole study population, and also by study.
The major independent variable was time measured in months. Up to 12 months of 
observations were assessed for each study. Studies varied in the amount of time observed. 
The shortest study followed patients for three months, one study followed patients for four 
months, two studies followed patients for six months, two studies followed patients for nine 
months, and six studies followed patients for 12 months.
Covariates included age in years, gender, education (high school graduate or less vs. more 
than high school education), race (White, African-American, Hispanic, or other), 
antiretroviral regimen (classified as NNRTI-based, PI-based, boosted PI-based, or other), 
history of substance abuse (yes/no), and whether the patient was ART naïve (yes/no).
Analyses
We plotted adherence by month, and then adherence by month for each individual study in 
order to visualize between study differences. Because these graphs suggested that there were 
considerable between study differences, and also that the relationship might be nonlinear, 
next we modeled the relationship between adherence and time using a cubic spline model 
with 12 knots. To estimate the possible underlying non-linear relationships, we used the 
generalized additive mixed model (GAMM) that is an extension of generalized linear mixed 
models (GLMMs). GAMM relaxes the assumptions of normality and linearity inherent in 
linear regression and allows the parametric fixed effects to be modeled non-parametrically 
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using additive smooth functions. The flexibility of non-parametric regression for the 
continuous predictors coupled with linear models for predictors provides a way to uncover 
structure within the data that may be missed using linear assumptions. GAMM modeling 
was carried out using the R Statistical Language and the MGCV Package.22 The model 
allows the assessment of the non-linearity of trend in the adherence curve, which is shown 
by the effective degrees of freedom (EDF) term from the model. An EDF of 1.0 denotes 
linearity, and values greater than 1.0 indicate non-linearity. The higher the edf, the more 
non-linear is the smoothing spline. The model also allows for assessment of the directional 
trend of the curve, that is, whether it is downward, flat, or upward trending.
We used a manual forward selection approach to select covariates, starting with a model that 
included study and a study by time interaction, and then sequentially testing the following 
variables: race, calendar year, regimen, ART naïve, and ART naïve by regimen. In each 
case, we used the likelihood ratio test to determine whether the added variable contributed 
significantly (p<0.05) to the model. For model diagnostics, we assessed 1) normality (the 
QQ-plot and the histogram of residuals), 2) homogeneity (residuals versus predictor plot, 
and residuals versus fitted values plot, also called the linear predictor plot for the Gaussian 
distribution with identity link), and 3) model fitting (fitted values versus observed values 
plot).
Formal modeling of missing data in longitudinal studies is complex.23 We were interested in 
determining whether those who dropped out of the 11 studies in our analysis were different 
from those who did not drop out, or, more formally, whether they were missing not at 
random.24 To test this, we estimated a Cox proportional hazards model with dropout as the 
dependent variable. Note that “dropout” here refers to study dropout, not treatment dropout 
(i.e., ARV non-persistence). The principal independent variable in the model was 
medication adherence. For those who did not drop out we used adherence in the last study 
month; for those who did drop out we used adherence in the month prior to dropout. 
Covariates included the same variables that were used in the models in which adherence was 
the dependent variable. This approach allows us to determine whether adherence prior to 
dropout predicted drop out.
RESULTS
Patient characteristics
Of the 916 patients studied, mean age was 41 years, and 35% were female (Table 2). 
Twenty-seven percent were White, 46% African-American, 21% were Hispanic, and 6% 
were classified as other. Eight-eight percent had a high school education or less. Seventy-
seven percent had a history of substance abuse. In approximately 27% an NNRTI was the 
monitored antiretroviral, in 17% it was a boosted PI, in 28% it was a PI, and in 28% it was 
an antiretroviral classified as other.
Changes in adherence over time
Unadjusted changes in adherence by month are shown in Figures 1 (all 11 studies 
aggregated) and 2 (each study individually). The base GAMM model that included only the 
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spline terms (12 knots) is shown in Figure 3. The EDF of the smoothed term for month in 
this model was 4.63, signifying high non-linearity. The model shows that the curve is down 
sloping (F=7.3, p<0.0001). The R-square of this base model was <0.01.
Variables that were statistically significant in the final, multivariable GAMM model 
included study, the study by time interaction, race, and calendar year. The R-squared of this 
final model was 0.14. These results are shown graphically in Figure 4, where the fitted 
adherence values for each study are plotted against time. The scale of both axes varies for 
each plot to allow appreciation of the study-by-study variation. For 3 of the studies (7,10, 
and 12), the EDF was 1.0, denoting a linear relationship between adherence and time. For 2 
of these studies (7 and 12), there was also a significant downward trend (p<0.0001), but for 
study 10, adherence did not decline (p>0.05). The relationship of adherence to time was 
non-linear for the remaining studies. For 6 of these (studies 1, 2, 8, 11, 13, and 15), there 
was a significant downward trend (p<0.05), and for 2 of these studies (5, and 6), there was 
no significant change in adherence over time (p>0.05). Model diagnostics, including 
normality, heterogeneity, and fit were acceptable. In the final model, African Americans had 
significantly worse adherence compared with Whites (7.9 points, p=0.0013). Calendar year 
was also significantly associated with adherence. Compared with year 1998, adherence was 
significantly better for years 1999 through 2006 and 2008, but was not significantly different 
for 2007.
We also tested a model that included an indicator variable for whether the study was a 
randomized trial or an observational study. The p-value for the indicator was 0.72.
Bias and missingness analysis
In a Cox proportional hazards model predicting study dropout that controlled for 
antiretroviral regimen and study, adherence was not associated with dropout (Hazard Ratio 
1.0, 95% CI 0.74-1.33, p=0.97).
DISCUSSION
There were three main findings from this research. First, across the 11 studies we studied, 
adherence declined with time, but this overall effect hides the fact that there was 
heterogeneity among studies in this decline. Second, the relationship between adherence and 
time was non-linear both overall and in the majority of individual studies. Third, covariate 
adjustment did not eliminate this heterogeneity.
Many of the previously published studies that address changes in adherence over time 
included patients from multiple clinical care sites.3,5,7,9,10,13,14,17 Only two of these studies 
included site as a variable in analyses. Maqutu et al.13 studied two sites in South Africa, and 
found that the rural site had adherence levels that were approximately 20 percentage points 
lower at study initiation than the urban site. They also found that the rate of increase in 
adherence in the rural site was significantly higher than that seen in the urban site (adjusted 
odds ratio for the rate of change was 1.06, p<0.004), such that both sites had approximately 
90% adherence after 18 months of follow-up. Muyingo et al.14 studied four sites in Uganda 
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and Zimbabwe. While they did not present data on changes over time by site, two of the 
sites had significantly higher (p<0.001) baseline adherence than the reference site.
Our data in combination with these other two studies that examined adherence levels by site 
suggest that aggregate data may often hide important study-level variation. This is not 
surprising. The 11 studies that we analyzed included both observational and intervention 
studies, and we have only limited data on the nature of adherence support for patients in 
these studies. While aggregated data is important for policy discussions, quality 
improvement requires care site specific data. That is, because historical factors, available 
resources, structural aspects of the delivery system, patient characteristics, and even 
provider incentives can differ widely from site to site, analyses of correlates or predictors of 
adherence and changes in adherence over time may yield site specific answers. We cannot 
know from these data why adherence in some studies declined with time and other studies 
did not. Answering this important question would require a study that collected a more 
extensive list of potential explanatory variables and that identified and characterized the care 
sites from which patients were recruited.
Overall, the relationship between adherence and time was non-linear, and it was non-linear 
for most of the studies. Existing studies use a variety of approaches to understanding 
changes in adherence with time, including descriptive measures,5-8,11,12 and more complex 
multivariable methods, often using generalized estimating equations (GEE) to account for 
repeated measures,1-3,9,10,13-17 and survival analysis.4 GEE's work on the population level, 
but their estimates of associations in smaller datasets are inefficient and sometimes 
inconsistent. GLMMs can model the adherence change on an individual level, but GAMMs 
allow flexible and non-linear specification of the dependence of the response variable on a 
set of temporal and/or spatial covariates without having to specify the model in terms of 
detailed parametric relationships, which made them more useful for the purposes of this 
analysis.
Another advantage of using models that capture nonlinearity is that we can address other 
hypotheses about how adherence as measured by EDM changes over time. For example, 
another possible interpretation for the decline in adherence that we saw is that in studies that 
use EDM there may be a Hawthorne effect. That is, participants who start using EDM have 
higher adherence than they would otherwise have by virtue of the fact that they know that 
their adherence is being measured or observed. Some studies support the existence of such 
an effect,25-28 but others do not.29 A pattern of adherence in which there was an increase in 
adherence followed by a decline (e.g., studies 6 and 8, Fig 4), or steeper declines in 
adherence in the first several months of treatment than what was seen later (studies 5, 13, 
and 15, Fig 4) would support the existence of Hawthorne effects. Thus our data provide only 
limited support for the assertion that Hawthorne effects are necessarily seen when EDM is 
used.
We were not surprised that adjustment for race and other covariates did not eliminate 
differences between sites. The finding that adherence was lower in African-Americans than 
Whites has been demonstrated in multiple other reports,30-35 including one from the 
MACH14 cohort.21
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There is variability in how prior researchers have dealt with loss to follow up. Some studies 
either do not mention loss to follow up or note that those lost to follow-up were excluded 
from analyses.1-4,7,9,10,12,14,15,17 Others presented descriptive information about rates of 
loss to follow-up or missing data, or in some way compare the full sample of those with 
missing data with those who had complete data or no loss to follow-up.5,6,8,11,16 Only one 
study explicitly analyzed loss to follow up.13 In our study, and also in Maqutu et al.,13 
analyses suggested that missing adherence values were missing completely at random, and 
therefore do not bias analyses, but this is a strong assumption, and we recommend that 
longitudinal studies of adherence formally examine the potential impact of loss to follow-up 
on their findings.
There were several study limitations. Regarding internal validity, we could not adjust for 
time on antiretroviral therapy prior to study entry, which, if it varied systematically between 
studies, could explain some of the observed variation. We also could not adjust for 
potentially important patient-level covariates including depression, income, social support, 
and patient provider relationship quality because these variables were not measured in all 
studies. Regarding generalizability, we studied a predominately treatment-experienced 
cohort cared for in the United States, and included only patients who agreed to use EDM. 
Thus our findings may not be generalizable to other populations or care settings. The studies 
we included were conducted over a time period during which there were important changes 
in ART regimens, particularly the addition of boosted-PIs and NNRTI's. However, our 
analyses controlled for calendar year, and regimen type was not associated with changes in 
adherence over time in our models, so we do not believe that this is an important limitation. 
Finally, the studies we analyzed were potentially different on multiple dimensions which we 
did not analyze, including the focus of the study (e.g., adherence in patients receiving 
methadone therapy), entry criteria (e.g., if only those with detectable viral loads were 
eligible to participate in an intervention trial), the nature of adherence support in study 
control arms, and the number of clinical care sites from which they recruited patients.
In conclusion, we found that, overall, adherence declined with time, but this was not 
consistent across studies. Studies that identify clinical and organizational factors associated 
with these different patterns are needed. Because this variability was not explained by the 
covariates we assessed, studies that look more carefully at how specific care processes may 
vary in the populations recruited by individual studies (e.g., availability of mental health 
services) are warranted. In conducting longitudinal analyses of adherence, our analysis 
suggests that investigators should take account of site and/or study effects and consider the 
use of non-linear models.
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Unadjusted adherence levels by study month (minimum, 25th percentile, median, 75th 
percentile, and maximum) for all 11 studies.
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Unadjusted adherence levels by study month (minimum, 25th percentile, median, 75th 
percentile, and maximum) for each study individually.
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Fitted values for adherence from GAMM by time. The y-axis shows the contribution of the 
smoother to the fitted values along with the 95% confidence band.
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Smoothed adherence curves over time for the 11 study sites, with 95% confidence bands. P-
values for the interaction between study site and time were significant for study 1 (p=0.013), 
study 2 (p=0.010), study 7 (p<.0001), study 8 (p<0.0001), study 11 (p=0.0002), study 12 
(p<0.0001), and study 13 (p<0.0001), study 15 (p=0.0001).
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Table 1
Descriptive characteristics of studies
Study # N Intervention Follow-up (months)
1 81 Yes 6
2 104 Yes 12
5 63 No 12
6 81 No 12
7 54 Yes 4
8 123 Yes 12
10 53 No 6
11 69 No 9
12 108 No 12
13 48 No 9
15 132 No 12
Totals 916













Wilson et al. Page 15
Table 2
Descriptive statistics of patients
Patient characteristics (N=916)
Age (years, mean (sd) 41 (8.2)
Gender (% female) 34.9
Race (%)
    White 27.1
    African-American 45.8
    Hispanic 21.1
    Other 6.0
Education (% HS or less) 88.1
Regimen type (%)
    NNRTI 27.1
    Boosted PI 16.9
    PI 28.1
    Other 27.9
Substance Use (% ever used, N= 570) 77.4
ART experienced (%, N=684) 76.2
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